Merck & Co postpones filing vicriviroc for HIV as two Phase III trials fail
This article was originally published in Scrip
Executive Summary
Merck & Co's CCR5 receptor antagonist vicriviroc has failed two Phase III trials in HIV, prompting the company to say that "it will not submit an [NDA] for vicriviroc in treatment-experienced HIV-infected patients at this time".